(HealthDay News) — Although three-fourths of US prostate cancer cases in 2003 to 2017 were localized, the incidence of distant-stage prostate cancer significantly increased during 2010 to 2017, according to a study published online in Morbidity and Mortality Weekly Report.
David A. Siegel, MD, from the US Centers for Disease Control and Prevention, and colleagues analyzed data from population-based cancer registries to provide recent data on prostate cancer incidence and survival in the United States.
The researchers found that localized-, regional-, distant-, and unknown-stage prostate cancer accounted for 77, 11, 5, and 7% of cases, respectively, among 3.1 million new cases of prostate cancer in 2003 to 2017, but the incidence of distant-stage prostate cancer increased from 4% in 2003 to 8% in 2017. Ten-year relative survival for localized-stage prostate cancer was 100% during 2001 to 2016. For distant-stage prostate cancer, 5-year survival improved from 28.7% in 2001 to 2005 to 32.3% during 2011 to 2016. Five-year survival was highest for Asian/Pacific Islanders, followed by Hispanics, American Indian/Alaska Natives, Blacks, and Whites (42.0, 37.2, 32.2, 31.6, and 29.1%, respectively) during 2001 to 2016.
“Understanding incidence and long-term survival by stage, race/ethnicity, and age could inform messaging related to the possible benefits and harms of prostate cancer screening and could guide public health planning related to treatment and survivor care,” the authors write.
Siegel DA, O’Neil ME, Richards TB, et al. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity – United States, 2001–2017. MMWR 69(41):1473–1480.